184 related articles for article (PubMed ID: 31434709)
1. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
Polesso F; Sarker M; Weinberg AD; Murray SE; Moran AE
J Immunol; 2019 Oct; 203(7):2011-2019. PubMed ID: 31434709
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
3. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
Kitamura N; Murata S; Ueki T; Mekata E; Reilly RT; Jaffee EM; Tani T
Int J Cancer; 2009 Aug; 125(3):630-8. PubMed ID: 19455675
[TBL] [Abstract][Full Text] [Related]
4. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
5. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
Nawaf MG; Ulvmar MH; Withers DR; McConnell FM; Gaspal FM; Webb GJ; Jones ND; Yagita H; Allison JP; Lane PJL
J Immunol; 2017 Aug; 199(3):974-981. PubMed ID: 28646041
[TBL] [Abstract][Full Text] [Related]
6. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
7. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
8. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
10. OX40 is a potent immune-stimulating target in late-stage cancer patients.
Curti BD; Kovacsovics-Bankowski M; Morris N; Walker E; Chisholm L; Floyd K; Walker J; Gonzalez I; Meeuwsen T; Fox BA; Moudgil T; Miller W; Haley D; Coffey T; Fisher B; Delanty-Miller L; Rymarchyk N; Kelly T; Crocenzi T; Bernstein E; Sanborn R; Urba WJ; Weinberg AD
Cancer Res; 2013 Dec; 73(24):7189-7198. PubMed ID: 24177180
[TBL] [Abstract][Full Text] [Related]
11. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
Voo KS; Bover L; Harline ML; Vien LT; Facchinetti V; Arima K; Kwak LW; Liu YJ
J Immunol; 2013 Oct; 191(7):3641-50. PubMed ID: 24014877
[TBL] [Abstract][Full Text] [Related]
12. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.
Xiao X; Gong W; Demirci G; Liu W; Spoerl S; Chu X; Bishop DK; Turka LA; Li XC
J Immunol; 2012 Jan; 188(2):892-901. PubMed ID: 22147766
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting OX40 Restores Regulatory T-Cell Function and Suppresses Inflammation in Pulmonary Sarcoidosis.
Kumari R; Chakraborty S; Jain R; Mitra S; Mohan A; Guleria R; Pandey S; Chaudhury U; Mitra DK
Chest; 2021 Sep; 160(3):969-982. PubMed ID: 33901497
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells: a potential target in cancer immunotherapy.
Shitara K; Nishikawa H
Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
[TBL] [Abstract][Full Text] [Related]
15. Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.
Ruby CE; Yates MA; Hirschhorn-Cymerman D; Chlebeck P; Wolchok JD; Houghton AN; Offner H; Weinberg AD
J Immunol; 2009 Oct; 183(8):4853-7. PubMed ID: 19786544
[TBL] [Abstract][Full Text] [Related]
16. OX40 costimulation turns off Foxp3+ Tregs.
Vu MD; Xiao X; Gao W; Degauque N; Chen M; Kroemer A; Killeen N; Ishii N; Li XC
Blood; 2007 Oct; 110(7):2501-10. PubMed ID: 17575071
[TBL] [Abstract][Full Text] [Related]
17. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
18. Signaling through OX40 enhances antitumor immunity.
Jensen SM; Maston LD; Gough MJ; Ruby CE; Redmond WL; Crittenden M; Li Y; Puri S; Poehlein CH; Morris N; Kovacsovics-Bankowski M; Moudgil T; Twitty C; Walker EB; Hu HM; Urba WJ; Weinberg AD; Curti B; Fox BA
Semin Oncol; 2010 Oct; 37(5):524-32. PubMed ID: 21074068
[TBL] [Abstract][Full Text] [Related]
19. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
20. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
Wang RF
Hum Immunol; 2008 Nov; 69(11):811-4. PubMed ID: 18817828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
